Literature DB >> 35035733

Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach.

Lívia Moreira Genaro1, Luís Eduardo Miani Gomes1, Ana Paula Menezes de Freitas Franceschini1, Hugo Dugolin Ceccato1, Rafael Nascimento de Jesus1, Amanda Pereira Lima1, Cristiane Kibune Nagasako2, João José Fagundes1, Maria de Lourdes Setsuko Ayrizono1, Raquel Franco Leal1.   

Abstract

Inflammatory bowel diseases are chronic illnesses that involve intestinal inflammation and are usually diagnosed as Crohn's disease or ulcerative colitis. As these diseases do not have a cure, the goal of treatment is to induce and maintain remission. Monoclonal antibodies have been recognized as the most advanced therapy to avoid complications and reduce the need for surgical approaches. However, although their effectiveness has been proven by several studies, they can trigger the immune system, induce the occurrence of immunogenicity, which may lead to the loss of response and treatment failure. The purpose of this review is to determine what are the main mechanisms involved in IBD; to assess the recommended treatments; to explore the mechanisms of immunogenicity. We also try to explain the detection and describe the existing advances that make possible the clinical application of these approaches. AJTR
Copyright © 2021.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; immunogenicity; monoclonal antibodies; ulcerative colitis

Year:  2021        PMID: 35035733      PMCID: PMC8748125     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  100 in total

Review 1.  TNF ligands and receptors--a matter of life and death.

Authors:  David J MacEwan
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Consensus guidelines for the management of inflammatory bowel disease.

Authors: 
Journal:  Arq Gastroenterol       Date:  2010 Jul-Sep

3.  Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab.

Authors:  S Mojtahed Poor; T Ulshöfer; L A Gabriel; M Henke; M Köhm; F Behrens; G Geisslinger; M J Parnham; H Burkhardt; S Schiffmann
Journal:  Clin Exp Immunol       Date:  2019-02-03       Impact factor: 4.330

4.  Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.

Authors:  J M Reimund; C Wittersheim; S Dumont; C D Muller; J S Kenney; R Baumann; P Poindron; B Duclos
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

5.  Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7.

Authors:  G Monteleone; T Parrello; F Luzza; F Pallone
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

6.  Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.

Authors:  R L West; Z Zelinkova; G J Wolbink; E J Kuipers; P C F Stokkers; C J van der Woude
Journal:  Aliment Pharmacol Ther       Date:  2008-08-08       Impact factor: 8.171

7.  Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA.

Authors:  Ming Han Lim; Kristina Aluzaite; Michael Schultz; Paul Casey
Journal:  J Gastroenterol Hepatol       Date:  2020-01-16       Impact factor: 4.029

8.  Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays.

Authors:  Cátia Rocha; Paula Lago; Samuel Fernandes; Luís Correia; Francisco Portela; Ana Isabel Vieira; Marta Patita; Bruno Arroja; Paula Ministro; Catarina Alves; Cláudia Camila Dias; Fernando Magro
Journal:  Therap Adv Gastroenterol       Date:  2020-11-18       Impact factor: 4.409

Review 9.  The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review.

Authors:  Charlotte Louise Maria Krieckaert; Geertje Margret Bartelds; Willem Frederik Lems; Gerrit Jan Wolbink
Journal:  Arthritis Res Ther       Date:  2010-10-20       Impact factor: 5.156

10.  Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.

Authors:  H Nakase; S Motoya; T Matsumoto; K Watanabe; T Hisamatsu; N Yoshimura; T Ishida; S Kato; T Nakagawa; M Esaki; M Nagahori; T Matsui; Y Naito; T Kanai; Y Suzuki; M Nojima; M Watanabe; T Hibi
Journal:  Aliment Pharmacol Ther       Date:  2017-09-08       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.